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Abstract
Background: Cervical cancer is the fourth most common cancer among women worldwide. Organized cervical 
screening and vaccination against human papilloma virus (HPV) have been successful interventions for prevention 
of invasive cervical cancer (ICC). Because of cultural and religious considerations, ICC has low incidence in Iran 
and many other Muslim countries. There is no organized cervical screening in these countries. Therefore, ICC 
is usually diagnosed in advanced stages with poor prognosis in these countries. We performed a priority setting 
exercise and suggested priorities for prevention of ICC in this setting.
Methods: We invited experts and researchers to a workshop and asked them to list important suggestions for ICC 
prevention in Iran. After merging similar items and removing the duplicates, we asked the experts to rank the 
list of suggested items. We used a strategy grid and Go-zone analysis to determine final list of priorities for ICC 
prevention in Iran.
Results: From 26 final items suggested as priorities for prevention of ICC, the most important priorities were 
developing national guidelines for cervical screening and quality control protocol for patient follow-up and 
management of precancerous lesions. In addition, we emphasized considering insurance coverage for cervical 
screening, public awareness, and research priorities, and establishment of a cervical screening registry.
Conclusion: A comprehensive approach and implementation of organized cervical screening program is necessary 
for prevention of ICC in Iran and other low incidence Muslim countries. Because of high cost for vaccination and 
low incidence of cervical cancer, we do not recommend HPV vaccination for the time being in Iran. 
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Implications for policy makers
• Policy-makers, scientific community, governmental agencies, private sectors, and non-governmental organizations (NGOs) should contribute 
to the planning and implementation of an organized cervical cancer prevention program. Cervical cancer screening and treatment services 
should be accessible and affordable for all women in the country
• Improvement of population-based cancer registry program and establishment of cervical screening registry are necessary for regular 
monitoring and evaluation of the screening program and should be prioritized in parallel to screening program. 
• Funding agencies should support research priorities suggested in this study. The results from these studies can be used for improvement of 
invasive cervical cancer (ICC) prevention in the future. 
Implications for public
We suggested prioritizing public awareness and providing necessary information to the women about cervical cancer prevention and importance 
of regular attendance in the cervical screening program. Women should consider the criteria of the national guideline for attendance in the 
screening program, including starting age, and screening intervals. As emphasized in this study, follow-up and management of the abnormal tests 
and precancerous lesions is crucial. Women who receive an abnormal result from screening test, must attend the healthcare centers or hospitals for 
further evaluation and necessary treatment. Otherwise, they may miss the opportunity for timely diagnosis and treatment of cancer. Unfortunately, 
the cancer patients with a delayed diagnosis would have poor prognosis and high mortality rate compared to the patients who are diagnosed earlier. 
Key Messages 
Introduction
Invasive cervical cancer (ICC) is the fourth most common 
cancer type among females worldwide.1 Human papilloma 
virus (HPV) is necessary cause for occurrence of cervical 
cancer.2 Organized cervical screening with Pap smear and 
HPV testing methods has led to prevention of ICC in the 
high income countries.3-5 Recently, the HPV vaccination 
was successfully introduced to prevent infection of  HPV 
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oncotypes and eradicate of cervical cancer.6 However, lack of 
organized cervical screening programs in low- and middle-
income countries (LMICs) has led to disparities and higher 
mortality to incidence ratios (MIRs) of ICC in these countries.1
For cultural and religious reasons, Muslim women abstain 
from sexual intercourse until their marriage and sexual 
relationship is restricted to their single partners7-9; therefore, 
cervical cancer has very low incidence rates in Iran and 
several other Muslim countries. For instance, the age 
standardized incidence rate (ASR) of ICC was estimated 
to be about 5 per 100 000 in Iran.10,11 As a result, ICC is not 
considered a major public health problem and most of these 
countries have no organized cervical screening program. 
Moreover, some Muslim women are reluctant to undergo 
cervical screening.7,12-15 Therefore, in spite of a low incidence 
rate, patients are usually diagnosed in advance stages and 
experience a poor prognosis.16
The resources for public health interventions are always 
limited, especially in the LMICs and public health 
organizations should choose among several options available 
to them. Therefore, they face challenges to prioritize among 
these options and to select the interventions that may have 
higher impact on improving the public’s health.17 The 
World Health Organization (WHO) considered the research 
priority setting as “the catalyst for public debate, for bringing 
together different stakeholders, and for creating networks.”18 
In addition, it was postulated that research priority setting 
leads to consensus about areas where increased research 
efforts including coordination, collaboration, and investment 
will increase the benefit to society.19 Priority setting is not 
limited to research programs and it is an important concept 
in public health programs. It is important to prioritize the 
interventions that have higher impact, in particular in the low 
resource settings. However, it is important to use an evidence 
base approach and involve wide range of stakeholders in the 
priority setting exercise.19 
We used a standard priority setting approach to develop a 
list of suggestions with higher priorities for ICC prevention 
in Iran. The results of this study will help the policy-makers, 
research community, and other stakeholders to take necessary 
actions and improve prevention of cervical cancer in the 
country. 
Methods
Two teams were involved in this priority setting exercise 
including the coordinating team and an expert panel. The 
coordinating team was responsible for methodological 
issues, literature review and coordination and management 
of the whole priority setting process. The expert panel was 
responsible to suggest priority items, participate in the 
technical and scientific discussion and rank them according 
to their expertise and the latest scientific evidence. Process of 
the priority setting exercise was summarized in Figure 1 and 
described in the following paragraphs.
Step 1- Literature Review
We reviewed the literature and assessed international and 
regional incidence and mortality rates of ICC, and different 
strategies for cervical prevention worldwide. In addition, we 
used data from Globocan 2012 and compared the incidence 
Figure 1. Priority Setting Process for Cervical Cancer Prevention in 
Iran in 2013.
and mortality rate of ICC in different countries.20 In addition, 
we studied incidence and mortality rates as well as the 
mortality to incidence ratio (MIR) of ICC in low incidence 
Muslim countries. 
Step 2- Team building
We identified and nominated national scientists with expertise 
in cervical cancer prevention. In addition, we identified 
policy-makers and organizations that were involved in 
cervical screening in the country. The expert were comprised 
of 19 clinicians (ie, 3 cancer surgeons, 2 pathologists, 3 
medical oncologist, 4 gynecologist, 1 radiotherapist, 2 nurse 
practitioner, and 4 obstetricians), 3 faculty members from 
nursing and midwifery department, 2 epidemiologists, 2 
experts in health policy and management, 1 health economist, 
and 3 officers from the Ministry of Health and Medical 
Education (MoHME).
Step 3- Priority Setting
Item Generation
We invited all the experts to a 3-day workshop, held in October 
2013 at the Cancer Institute of Iran. Overall, 30 individuals 
(68% female and 32% male) from different disciplines 
participated in the workshop. The workshop was organized 
with a grant from Union International Cancer Control 
(UICC) and the lectures were provided by both international 
and local speakers. During the workshop, we provided latest 
information and evidences about cervical cancer prevention 
in Iran and other countries, international variation about 
burden of cervical cancer, recommendations about cervical 
screening programs, screening tests (ie, Pap smear, HPV 
testing, visual inspection with acid acetic), HPV vaccination, 
guidelines on management of cervical precancerous lesions, 
and comparison of opportunistic and organized cervical 
screening program.
A few days before the workshop, we asked all invitees to 
prepare and bring their suggestions about improvement of 
ICC prevention program in Iran to the meeting. Specifically, 
we asked them to answer the following questions:
 
Litrature Review
(Coordinating Team)
Workshop for the 
Niminated Experts
(Exper Panel)
Item Generation 
(Expert Panel)
Item Reduction
(Coordinating team)
Ranking
(Expert Panel)
Analyses of Scores
(Coordinating Team)
Re-Ranking
(Expert Panel)
Go-Zone Analysis
(Coodrinating Team)
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1)	 What are the three priorities for improvement of ICC 
prevention in Iran?
2)	 What are the most challenging issues about ICC 
prevention in Iran?
On the first day of the workshop, we presented detailed 
information about methodology of the priority setting and 
clarified their role in the process. Afterwards, we provided a 
list of most recommendations for ICC prevention which had 
been extracted from literature as well as the responses we 
received from the participants before the workshop. We asked 
the participants to review the initial list and add additional 
items if necessary.
Item Reduction and Clustering
The list of items that were generated in previous steps was 
comprised of 83 subjects. We reduced the list down to 26 items 
after elimination of duplicates and merging of overlapping 
items. The final list was categorized into 5 clusters:
1)	 Planning of ICC prevention program
2)	 Implementation of the programs
3)	 Quality control program
4)	 Epidemiological and clinical research
5)	 Training and health promotion activities.
Ranking
In the second day of the workshop, the participants reviewed 
the final list and ranked them in 2 dimensions of importance 
and feasibility, using a 1-9 point Likert scale system, in which 
score one denoted as the least important/feasible and score 
9 denoted as the most important/feasible intervention for 
improvement of cervical cancer prevention in Iran. 
Re-ranking
One month after the first round of the ranking, we invited the 
expert panel to the second meeting and asked them to review 
the results of initial ranking and confirm or revise them if 
necessary. The results were discussed in the second meeting 
and the panelists ranked the items again for second round. 
Go-Zone Analysis
We used a scatter plot to create go-zone figures, in which 
we plotted the average of the importance (Y axis) against 
feasibility (X axis) scores (Figure 2).21 The figure was divided 
into four quadrants (zones) through two perpendicular lines 
indicating the average of X and Y axes. The four-quadrant 
scatter plot categorized the items into four groups. The most 
important and feasible items were located in the right-upper 
quadrant (RUQ) and the least important and feasible items 
were located in the left-lower quadrant (LLQ). Finally, the 
items which were located in the RUQ considered as the top 
priorities for prevention of ICC in Iran. We used Excel and 
SPSS version 17.0 software for statistical analyses.
Results
We observed the lowest incidence rates of ICC for Western 
Asia (ASR = 4.4), Australia and New Zealand (ASR = 5.5), 
North Africa (ASR = 6.6), North America and Canada 
(ASR = 6.6), and Western Europe (ASR = 7.3). However, MIR 
was higher in Western Asia (MIR = 0.43), and North Africa 
(MIR = 0.48) compared to Australia (MIR = 0.27), Western 
Europe (MIR = 0.25), and North American (0.25) (Figure 3). 
African countries had the highest incidence and mortality 
rates of ICC. Evaluation of ICC statistics in Muslim countries 
which mostly located in the Middle East and North Africa, 
showed that although the ASR of ICC was low in most of the 
Muslim countries, MIR was higher than 0.40 in all countries, 
except for Bahrain in which the MIR was 0.32 (Figure 4).
In overall, 26 suggestions were provided by the expert panel 
for improvement of cervical cancer prevention in Iran (Table). 
The suggested actions were categorized in six areas including 
(1) planning, (2) program implementation, (3) quality control 
program, (4) research, and (5) health promotion and training.
Top priorities for ICC prevention in Iran which were located 
in the URQ and were both important and feasible include:
1.	 Developing a national guideline and defining appropriate 
screening test, starting age and interval for regular 
screenings (item 1);
2.	 Developing quality control protocols for follow-up and 
management of the patients with precancerous lesions 
and cervical cancer patients (item 11);
3.	 Conducting a cost-effectiveness study for HPV 
vaccination in Iran (item 12);
4.	 Coverage of the cervical screening by insurance 
companies (item 4);
5.	 Using an electronic registration system for cervical 
screening program (item 8);
6.	 Evaluating the role of partners/husbands in cervical 
screening (item 18);
7.	 Increasing public awareness about cervical cancer 
screening through mass media, including internet, TV, 
radio, newspapers, and etc. (item 26);
8.	 Regular monitoring of the incidence and prevalence of 
precancerous lesions (item 20).
Discussion
Incidence rate of ICC is relatively low in Iran and other 
Muslim countries; however, the patients are diagnosed in 
advanced stages and experience poor prognosis, leading 
to a high MIR in these countries. In this study, we defined 
Figure 2. Go-Zone Analysis for 26 Suggested Statements. Each 
numbers indicates an ID of the suggested item (see Table).
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priorities for ICC prevention in Iran. The most important 
priorities were developing a national guideline for organized 
cervical screening program, and a quality control protocol 
for cervical screening processes, including the follow-up and 
management of patients with precancerous lesions. 
Development of a national program for ICC prevention 
was the most important suggestion. It was emphasized that 
the new plan should consider the best strategy for the type 
of screening test, starting age for screening, and screening 
intervals. In addition, development of the national guideline 
for management of precancerous lesions and patient follow-
ups were prioritized in this study. According to current 
screening guideline in Iran, all women above 21 years of age 
who had sexual activity are recommended to attend cervical 
screening every three years. Cervical screening is offered in 
healthcare centers all over the country; however, there is no 
active invitation or awareness program to increase motivation 
of the women to participate in the screening. Women who 
are health conscious and those who visit a gynecologist or an 
obstetrician for any reason are advised to participate in cervical 
screening.11 Therefore, most women particularly those from 
low socio-economic groups who are usually at a higher risk 
for cervical cancer refrain from participation in the screening 
program. This type of program which is called “opportunistic 
screening” was shown as non-efficient approach for prevention 
of ICC. In the opportunistic screening, the coverage is usually 
low and ICC prevention program is inefficient, leading to 
the diagnosis of ICC patients in advanced stages.1,9,22 Sancho-
Garnier et al23 reported that most of the extended Middle 
East and North African (MENA) countries that lack national 
guideline and resources for the management of abnormal 
lesions. They showed that the main obstacle to develop such 
a national program in these countries has been the lack of 
political understanding and providing necessary resources for 
cervical screening program. 
There is a wide variation in the cervical screening strategies 
in different countries.24 The main variations are related to 
type of screening test, starting age, and screening intervals. 
HPV testing, Pap smear tests, and visual inspection with 
acetic acid (VIA), are three types of screening tests that are 
used for cervical screening worldwide.1 Sensitivity, specificity 
and cost-effectiveness are important parameters for decision 
about type of the test, starting age, and screening intervals in 
the ICC prevention program. Because of the low incidence 
Figure 3. International Variation of Age Standardized Incidence (ASR) and Mortality (ASMR) Rates Per 100 000 Women and ASMR/ASR Ratio 
(Source: Globocan 2012).
Figure 4. Age Standardized Incidence (ASR) and Mortality (ASMR) Rates Per 100 000 Women and ASMR/ASR Ratio Among Low Incidence  
Muslim Countries (Source: Globocan 2012).
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rate of cervical cancer in Iran, there are several proposals 
to increase the starting age from 21 to 30 or 35 years and 
increase the screening interval from 3 years to 5 years.11,25 A 
cost-effective analysis will suggest optimal strategy vis-à-vis 
cervical screening in Iran and other Muslim countries. 
We emphasized that cervical screening should be free of charge 
with a full insurance coverage for all women. Otherwise, most 
of the Iranian women cannot afford cost of cervical screening 
test and follow-up procedures. Cronjé et al found that 
affordability and coverage were the most important obstacles 
for implementation of national cervical screening programs 
in low resource countries.23,26 Since 2014, Iranian government 
has increased the health insurance coverage and all the 
inpatient costs in the governmental hospitals became free for 
all patients. Under this reform, management of the patients 
with precancerous lesion will be covered by insurance benefit 
packages in Iran. However, screening test and evaluation 
of the screening samples is not covered yet and could be a 
major barrier for implementation of an organized screening 
program. Choosing a cost-effective strategy for cervical 
screening and decision about type of test, starting age and 
screening intervals are necessary parameters for estimation of 
the screening cost and introduction of the screening service 
in the insurance package.27 Therefore, the panel suggested 
starting the negotiation with the insurance companies to 
cover the cost of screening in their benefit package. 
Lack of awareness was reported to be a major factor that may 
influence participation of women in cervical screening.28,29 In 
addition to the affordability and access to cervical screening 
service, awareness and positive attitudes of women and their 
families about cervical screening is an important factor 
for success of screening program.30-32 Several studies have 
reported that Iranian women have little information about 
cervical screening and importance of ICC prevention.31,33 This 
study emphasizes that health promotion activity should be 
prioritized in the new organized program and use appropriate 
health promotion model for motivation of general population 
and participation of women in the screening program. 
The other important priority was improvement of cancer 
registry, and considering a registration system for screening 
program. Iran has a national pathology-based cancer registry 
program. However, studies showed that quality of this registry 
is not convincing in Iran.34 Only one population-based cancer 
registry (PBCR) which is established in Golestan province in 
the northeast of Iran has so far met the standard criteria and 
received approval from International Agency for Research 
on Cancer (IARC). The results of Golestan province PBCR 
was published in the IARC book “Cancer in Five Continents, 
Version X” in 2013.20 ASR of cervical cancer in Golestan 
province and in the report of PBCR of Tehran was about 
Table. Suggested Statements Clustered and Ranked Based on Importance and Feasibility for Each Cluster
Clusters Statements in Each Cluster (Statement ID) Importance Feasibility
Planning
Developing a national ICC prevention guideline and defining appropriate screening test, starting age and 
interval for regular screenings (1)
8.4 6.6
Developing protocols for screening process and follow-up of the patients with precancerous lesions (2) 7.5 5.2
Implementation 
of screening 
programs
Using an electronic registration system for screening data (8) 8.6 5.9
Coverage of cervical screening by insurance companies (4) 8.4 6.9
Providing necessary equipment and resources to laboratories for screening test (kits, instruments, 
personnel, and etc.) (7)
8.5 4.8
Engagement of family physicians and healthcare system in cervical screening (5) 8.2 4.8
Elimination of legal boundaries and implementing an organize cervical screening by MoHME (3) 9.0 4.1
Using appropriate screening strategy to increase the participation rate in the screening program (6) 7.9 4.1
Quality control 
program
Developing quality control protocols for the process of patient follow-up (ie, management of precancerous 
lesions and the treatment of cancer patients) (11)
8.6 6.5
Developing quality assurance protocols for laboratories that are involved in the screening program (9) 8.7 5.3
Developing quality assurance protocols for management of the screening program in terms of accuracy and 
coverage (10)
4.4 4.6
Research
Evaluating the role of partners/husbands in participation of women in cervical screening (18) 8.5 5.8
Conducting cost-effectiveness study for HPV vaccination in Iran (12) 8.1 5.7
Regular monitoring of the incidence and prevalence of precancerous lesions (20) 7.7 5.9
Evaluation of benefits and requirement for using Liquid Base Cytology technique for cervical screening test 
(15) 7.3 7.0
Identifying the incentives and barriers for participation in cervical cancer screening in the country (14) 7.3 6.2
Nationwide study of survival rate and prognostic factors for cervical cancer (22) 7.7 5.3
Determining the risk factors of cervical cancer specially determining variations in high risk behaviors 
associated with the incidence of cervical cancer among young people (13)
7.2 6.1
Identifying the knowledge, attitude, and practice of target group women and healthcare providers about 
cervical cancer screening programs (16)
7.6 5.0
Determining the prevalence of HPV infection and precancerous lesions among high-risk groups (17) 7.1 5.0
Conducting a demonstration project for organized screening program in a selected province (24) 8.1 3.8
Accurate assessment of the incidence, prevalence and mortality of cervical cancer (23) 6.5 4.4
Evaluation of sero-epidemiology of HPV infection in general population (21) 6.6 3.9
Research on epidemiology of genital warts (19) 6.2 5.4
Health 
promotion and 
training 
Increasing public awareness about cervical cancer screening through mass media (Internet, TV, radio, 
newspapers, etc.) (26)
8.1 6.2
Training of clinicians and other healthcare providers about cervical screening programs (25) 7.6 6.2
Abbreviations: ICC, invasive cervical cancer; MoHME, Ministry of Health and Medical Education; HPV, human papilloma virus.
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5-6 per 100 000,11,35 which was about 50% higher than rates 
reported by the national pathology-based cancer registry in 
Iran,36 indicating that pathology-based registry underestimate 
the incidence rate in Iran. Therefore, improvement of PBCR 
is necessary for evaluation of the cervical cancer prevention 
program. In addition, we suggested establishing a cervical 
screening registry and registration of women who participate 
for screening and their follow-ups. Such a system would be an 
important component of the screening program and can help 
public health managers to work efficiently.37 Screening registry 
will provide information about timing of screening visits for 
target women, compliance, and follow-up information about 
women with abnormal screening tests. Linkage of screening 
registry and cancer registry data would provide opportunity 
for regular audit of screening program.38,39
Bivalent HPV vaccine immunizes women against HPV 16, 
and 18, and quadrivalent vaccine additionally protects against 
genotypes 6, and 11. Both vaccines has shown efficacy of over 
90% against persistent HPV infection.40 Several high-income 
countries have introduced HPV vaccination and try to 
increase the coverage of vaccination. HPV vaccination could 
be an effective intervention for ICC prevention in developing 
world in which screening is available or effective.41 However, 
cost of the vaccine is considerably high and the price is a 
major barrier for administration of the vaccine in developing 
countries including Iran. Because of the low incidence rate of 
cervical cancer and very high cost for HPV vaccination, it was 
not considered as a priority for the time being in Iran. Instead, 
the panel members suggested conducting a cost-effective 
study for HPV vaccination in Iran. After this workshop, 
Khatibi et al42 evaluated cost-effectiveness of the quadrivalent 
vaccine and found that HPV vaccination was not cost-
effective for Iran. However, the situation may be changed in 
the future, when the incidence rate of cervical cancer is higher 
or a cheaper vaccine is available.
This study was the first exercise to develop list of priorities 
for ICC prevention in Iran. The identified priorities introduce 
comprehensive recommendations covering all aspects of ICC 
prevention in Iran, including the program planning, quality 
assurance, public awareness, and research. The attendees in our 
meetings were multidisciplinary group, including academic 
and non-academic experts in the field of ICC prevention. 
However, we faced some limitations in this study. One of 
the most important principles in priority setting for public 
health issues is the involvement of community and taking 
the viewpoint of the general public.43-45 Unfortunately, we 
could not involve community members in this study because 
the workshop was a scientific event which was conducted in 
English. We suggest involvement of the community, including 
health women, and cervical cancer patients in the future 
analyses.
Conclusion
This priority setting exercise provided important suggestions 
for prevention of ICC in Iran. Our recommendations can be 
generalized to other low incidence Muslin countries that lack 
an organize ICC prevention program. This study implied 
that policy-makers should prioritize implementation of 
organized cervical cancer prevention, through development 
of a national guideline for cervical screening. In addition, 
implementing a quality assurance program for all procedures 
of ICC prevention is necessary to make sure that the program 
will efficiently decrease the burden of cervical cancer. HPV 
vaccination was not considered a priority for the time being 
in Iran. 
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